Should SGLT2 Inhibitors Be Stopped for Recurrent UTI?
SGLT2 inhibitors should NOT be routinely discontinued for recurrent urinary tract infections in patients with type 2 diabetes, chronic kidney disease, or heart failure, given their proven mortality and cardiovascular benefits far outweigh the manageable risk of genitourinary infections. 1, 2
Evidence-Based Rationale
Cardiovascular and Renal Benefits Trump Infection Risk
- Permanent discontinuation of SGLT2 inhibitors results in rapid loss of cardiorenal benefits, including increased risks of all-cause mortality, cardiovascular death, kidney failure, and heart failure hospitalization 1
- The threshold for discontinuing SGLT2 inhibitors due to UTI concerns should be high for persons with heart failure, diabetes, and CKD 2
- KDIGO 2022 guidelines make no mention of UTI as an indication to discontinue SGLT2 inhibitors, despite acknowledging increased infection risk in immunosuppressed patients 3
UTI Risk Is Not Significantly Elevated
Contrary to common concerns, recent high-quality evidence challenges the assumption that SGLT2 inhibitors increase UTI risk:
- A 2023 nationwide Japanese claims database analysis found no evidence that SGLT2 inhibitors increase UTIs in patients with diabetes, regardless of sex or age 4
- In male patients with diabetes, SGLT2 inhibitor prescription was negatively associated with UTI likelihood (OR 0.74,95% CI 0.72-0.75) 4
- A 2024 cross-sectional study of 328 patients found no statistical difference in UTI presence between patients taking SGLT2 inhibitors versus other glucose-lowering medications 5
- Large cardiovascular trials showed no difference in rates of any urinary tract infections or serious urinary tract infections between SGLT2 inhibitors and placebo 6
Post-UTI Outcomes Actually Favor SGLT2 Inhibitor Use
- A 2025 retrospective cohort study demonstrated that initiating SGLT2 inhibitors within 90 days after UTI was associated with lower mortality (HR 0.59,95% CI 0.45-0.77), reduced kidney complications (HR 0.78), and decreased sepsis risk (HR 0.75) compared to DPP-4 inhibitors 7
- These findings support the safety and clinical benefit of continuing or initiating SGLT2 inhibitors during the post-infectious phase, even after recent UTI 7
Clinical Management Algorithm
When to Continue SGLT2 Inhibitors (Most Patients)
Continue therapy if:
- UTIs are mild to moderate in severity 1
- Infections respond to standard antimicrobial treatment 1
- Patient has established cardiovascular disease, heart failure, or CKD with eGFR ≥20 mL/min/1.73 m² 3, 8
- No severe or persistent contraindications exist 1
Preventive Strategies to Minimize UTI Risk
Before initiating SGLT2 inhibitors, identify high-risk patients: 1
- Prior history of recurrent genitourinary infections 9
- Uncontrolled hyperglycemia (higher HbA1c increases UTI risk) 5
- Older adults 9
- Uncircumcised males 9
- Female gender (higher baseline UTI risk) 5
Implement preventive measures: 10
- Ensure adequate hydration to promote frequent urination
- Encourage urge-initiated voiding and post-coital voiding
- Avoid spermicidal-containing contraceptives
- For postmenopausal women with atrophic vaginitis, prescribe topical vaginal estrogens
- Daily hygienic measures to reduce genital mycotic infection risk 8
When Temporary Discontinuation May Be Warranted
Consider temporary withholding only during: 3
- Prolonged fasting, surgery, or critical medical illness (ketoacidosis risk, not UTI-related)
- Active severe or complicated UTI requiring hospitalization (resume as soon as clinically stable)
The threshold for reinitiation should be low once the acute infection is treated 2
Common Pitfalls to Avoid
Pitfall #1: Confusing Genital Mycotic Infections with UTIs
- Genital mycotic infections (candida vaginitis, balanitis) occur in 6% of SGLT2 inhibitor users versus 1% with placebo 8
- These are not UTIs and are easily treated with brief antifungal courses, rarely requiring SGLT2 inhibitor discontinuation 6
- Most genital infections do not recur after treatment 6
Pitfall #2: Overestimating UTI Risk Based on Mechanism
- While increased glucosuria theoretically creates favorable conditions for bacterial growth, real-world data does not support increased UTI incidence 5, 4
- Poor glycemic control (higher HbA1c) and higher BMI are stronger UTI predictors than SGLT2 inhibitor use itself 5
Pitfall #3: Failing to Address Modifiable Risk Factors
- Before discontinuing SGLT2 inhibitors, optimize glycemic control and address anatomical/functional urinary tract abnormalities 10
- Recurrent UTIs in women <40 years without risk factors do not warrant extensive workup or SGLT2 inhibitor discontinuation 11
Special Populations
Kidney Transplant Recipients
- SGLT2 inhibitors have not been adequately studied in kidney transplant recipients who are immunosuppressed and potentially at increased infection risk 3
- The recommendation to use SGLT2 inhibitors does not apply to this population 3
Older Men with Voiding Dysfunction
- A 2025 VigiBase analysis found elevated risk for complex UTIs in men ≥65 years (ROR 8.79,95% CI 6.79-11.37), likely related to benign prostatic hyperplasia 12
- However, this represents a signal for monitoring, not automatic discontinuation, given the substantial cardiovascular and mortality benefits 2
Bottom Line
Most genitourinary infections associated with SGLT2 inhibitor therapy are mild to moderate, respond to standard antimicrobial treatment, and do not require drug discontinuation. 1 The proven reductions in all-cause mortality, cardiovascular death, and kidney failure progression justify continuing therapy in the vast majority of patients with recurrent UTIs. 3, 8, 7